Merck and Moderna announced that a large trial of a personalised mRNA cancer therapy succeeded in melanoma. The coverage called it a landmark. This is what was actually released, what was not, and what the numbers underneath it will and will not support.
The Phase 3 announcement reports no Phase 3 results. It describes the trial in detail, and it does quote hazard ratios — but every one of them belongs to an earlier, smaller trial. Of the study it is actually announcing it says only that the endpoints were met, "statistically significant and clinically meaningful." No hazard ratio, no interval, no p-value, no percentage.
So the numbers carried in the coverage — the 49% reduction, the 59% reduction — describe a different trial: an open-label study of 157 patients, not the blinded study of 1,137 that was announced.
And the one endpoint that would tell you whether anyone lives longer rests, at five years, on an analysis the companies label only "n=14". They call it an encouraging trend. The range around it runs from an 84% reduction in the risk of death to a 35% increase.
None of this means the treatment does not work. It probably does. It means the public has not been shown how well, and the numbers being repeated are carrying more weight than they can bear.
The distinction the coverage collapsed.
On 19 August 2026, Merck and Moderna announced that INTerpath-001 — a randomised, double-blind, placebo- and active-comparator-controlled Phase 3 trial in 1,137 patients — met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival at an interim analysis.
That is a real and significant result. A double-blind trial of that size is the strongest instrument this field has, and it agreed with the smaller study that preceded it.
The release contains no hazard ratio, no confidence interval, no p-value and no percentage describing the size of that effect. It does contain hazard ratios — 0.510 for recurrence, 0.411 for distant metastasis — but those are the five-year results of KEYNOTE-942, the 157-patient trial that preceded this one, and the release says so. Of the 1,137-patient trial it is announcing, the quantitative content is nil. A week on, it still is. The companies say the data "will be presented at an upcoming international medical meeting and shared with regulatory authorities."
Our first draft of this piece accused the coverage of passing those figures off as the Phase 3's own. Then we checked, and that is not what happened. Every outlet we could reach attributed them correctly to KEYNOTE-942, and several noted explicitly that the Phase 3 numbers were withheld. We were wrong and we have cut the accusation.
What is left is subtler and harder to fix. The figures are correctly attributed and still doing work they cannot do. A reader who sees "49% reduction" three paragraphs under "Phase 3 succeeds" comes away with a sense of how large this effect is. That sense is drawn from 157 unblinded patients, and the study that could correct it has published nothing. Nobody has to be careless for that to happen.
Five terms that carry almost all the meaning, each explained with a real number from this story.
A comparison of how fast something is happening in two groups. An HR of 1.0 means the groups are identical. Below 1.0 means the treatment group is doing better; above 1.0 means worse.
The value is a rate, not a headcount. An HR of 0.51 does not mean 49% of patients were saved. It means that at any given moment during the trial, someone in the treatment group was recurring at about half the rate of someone in the comparison group.
Every trial measures a sample, not the world. The confidence interval is the range of true effects reasonably consistent with what the researchers saw. A narrow interval means the trial pinned the answer down. A wide one means it did not.
The single most useful question to ask of any interval: does it cross 1.0? Because 1.0 means no difference at all. If the range includes 1.0, then "this treatment does nothing" is still among the possibilities the data cannot rule out.
All four intervals are from KEYNOTE-942, the 157-patient Phase 2b. Amber bars cross the no-effect line; green ones clear it. The Phase 3 has no bar here, because it has published no numbers.
The probability of seeing a result at least this good if the treatment actually did nothing. A small p-value means the result would be a surprising fluke. By convention, below 0.05 is called statistically significant — an arbitrary line, but a widely used one.
Before a trial starts, researchers register one main question and a statistical threshold for answering it. "Met its primary endpoint" means the threshold was crossed. It is a pass/fail statement.
It contains no information about size. A therapy that reduces recurrence by 8% and one that halves it both produce that sentence. This is why the absence of a hazard ratio in the Phase 3 announcement matters: "met its endpoint" is the floor of what could be said, not a summary of what was found.
Three different questions, routinely blurred together in coverage.
Recurrence-free survival (RFS) — how long until the cancer comes back anywhere, or the patient dies. Distant metastasis-free survival (DMFS) — how long until it spreads to distant organs, the more dangerous kind of return. Overall survival (OS) — how long until death, from any cause.
Coverage has been merging them. Different sizes, different patients, different rigour — and only one has published numbers.
| KEYNOTE-942 | INTerpath-001 | |
|---|---|---|
| Phase | 2b | 3 |
| Patients | 157 (107 vs 50) | 1,137 (2:1) |
| Population | Stage IIIB–IV resected | Stage IIB–IV resected |
| Blinding | Open-label — everyone knew who got what | Double-blind, placebo- and active-comparator-controlled |
| Recurrence-free survival | HR 0.510 (0.294–0.887) at 5 years | met endpoint · not released |
| Distant metastasis-free | HR 0.411 (0.200–0.843) | met endpoint · not released |
| Overall survival | HR 0.471 (0.165–1.345) exploratory, "n=14" | still being measured |
KEYNOTE-942 was open-label: patients and doctors both knew which arm they were in, and the primary endpoint was judged by those same investigators. That is a genuine weakness. A doctor who knows a patient received an experimental therapy may, entirely unconsciously, scan and interpret differently.
The Phase 3 substantially reduces that problem. It is double-blind and placebo-controlled, so nobody assessing a recurrence knows which treatment produced it. It is the more trustworthy trial by a wide margin — seven times larger, and blinded against exactly the bias the earlier one carried. Which is precisely why it is frustrating that its numbers are the ones we do not have.
It does not eliminate the problem, though, and that has had little attention. Merck's own description of the Phase 3 defines its primary endpoint as recurrence "as assessed by the investigator" — the same mechanism as the open-label trial. Blinding stops an assessor knowing which arm a patient is in. It does not replace the assessor with an independent review committee, which is the design that removes the judgement altogether. Better, then, but not solved.
KEYNOTE-942 enrolled stage IIIB–IV. The Phase 3 enrolled stage IIB–IV, which widens the population at both ends — down into IIB and IIC, and into IIIA, none of which the earlier trial included. Those patients start at lower risk of recurrence, which leaves less room for absolute benefit. Whether the effect holds up across that wider range is a real open question, and exactly the kind of thing a subgroup breakdown would answer.
As of 26 August 2026.
Our published six-dimension rubric, applied by hand. The arithmetic is shown so you can disagree with it.
This is not engine output. Melanoma is not one of the topics our pipeline covers, so nothing here was produced by the scoring system that runs the site. One of us applied the published rubric to one claim, by hand, and the working is below.
We are also part-way through rebuilding how the engine reaches a verdict, for reasons set out in Who Pays for This. Publishing a machine score today would imply a confidence in that machine we do not currently have.
"Intismeran autogene plus pembrolizumab improves recurrence-free survival versus pembrolizumab alone in resected stage IIB–IV melanoma."
The two extremes are the whole story. Rigor scores 5 — a double-blind, placebo-controlled, 1,137-patient Phase 3 is as good as trial design gets. Data support scores 1 — the rubric's anchor for 1 is "no data cited," and for the size of the effect, none was.
So the study is excellent and the evidence released about it is almost nothing. Those are different things, and a scoring system worth having has to be able to say both at once. Source quality scores 3 rather than 5 for the same reason: the claim currently rests on a corporate press release, which the rubric ranks as industry analysis, not the peer-reviewed publication it will eventually become.
This is what a headline cannot do. "Landmark trial succeeds" and "3.4, moderate" describe the same event, and only one of them tells you the numbers are still missing.
The full Phase 3 dataset — presented at a medical meeting or published in a journal, with the hazard ratio, the confidence interval and the breakdown by disease stage. That single release converts this from a directional claim into a measurable one, and would move data support from 1 to 4 or 5 and source quality from 3 to 5. Expect the score to move by roughly a full point when it lands, in whichever direction the numbers point.
Overall survival, on enough events to mean something. Until it reads out, the honest sentence is that this therapy delays recurrence — not that it extends life.
The part of this that is not academic.
This treatment is not available. It is investigational, approved by no regulator, and cannot be prescribed. The only route to it is a clinical trial.
We assess published evidence. This is not medical advice, cannot account for your individual situation, and is no substitute for your oncologist — who can see your pathology, your stage and your history, none of which a page like this knows.
Primary sources first. Every number above traces to one of these, and none to a news report.